Merck has acquired Australian listed cancer research firm Viralytics in a $502 million deal.
The 20th annual Science meets Parliament was attended in record-breaking numbers, bringing more than 240 Australian scientists to Canberra for a chance to meet with parliamentarians.
Professor Dayong Jin will spearhead the institute's efforts to create small, stable, inexpensive devices for disease diagnosis that are as easy to use as smartphones.
Researchers have recommended changes to the guidelines used in clinical trials, in an effort to gain information about the impact on the quality of life of participating patients.
Researchers at the University of Technology Sydney have developed a new microscopy technology that allows the human eye to track a single molecule and inspect its behaviour inside a living cell.
Thirteen medical researchers and projects tackling critical health issues across northern Australia have received government funding.
Following an extensive consultation process, Innovation and Science Australia's strategic plan for Australian innovation has finally been made public.
Veteran immunologist Jacques Miller has been awarded the 2018 Japan Prize.
JJIPO@MONASH will be the Victorian headquarters for Johnson & Johnson's scientific, investment and commercialisation arms.
A new report has revealed favourable insights into clinical trials in Australia, where more than $1 billion is invested each year by both government and industry.
The Australian Government has announced that it will permit the export of medicinal cannabis products.
UNSW Sydney has announced the part-time appointment of its first Nobel Laureate, Sir Fraser Stoddart, to the School of Chemistry.
Merck has entered into an agreement with Avanti Polar Lipids to be the exclusive multinational distributor of the latter's research lipids portfolio outside of the United States.
Scientist and angel investor Dr Jay Hetzel has been appointed chairman of UniQuest, The University of Queensland's commercialisation company.
The overall market value of in vitro diagnostics stands at US$52 billion this year and is projected to grow at a compound annual growth rate of 4.2% to US$69 billion in 2024, according to GlobalData.